Overview
Thalassemia intermedia (TI) is a form of inherited hemoglobinopathy characterized by milder clinical manifestations compared to β-thalassemia major, often requiring less intensive management but still susceptible to complications such as iron overload and organ dysfunction.Diagnosis
Clinical Presentation: Variable anemia, splenomegaly, and symptoms related to iron overload.
Laboratory Tests: Hemoglobin levels, mean corpuscular volume (MCV), and elevated ferritin levels indicative of iron overload.
Imaging: MRI for detecting silent brain infarctions; PET-CT can reveal decreased neuronal function, particularly in temporal and parietal lobes, complementing MRI findings 1.
Iron Concentration: Elevated liver iron concentration (>15 mg Fe/g dry weight) correlates with decreased neuronal function 1.Management
Transfusion Therapy: Protective against thrombosis, extramedullary hematopoiesis (EMH), pulmonary hypertension (PHT), heart failure, cholelithiasis, and leg ulcers; however, increases risk of endocrinopathies 2.
Iron Chelation Therapy: Protective against endocrinopathies and PHT 2.
Hydroxyurea: May increase risk of hypogonadism but protective against EMH, PHT, leg ulcers, and hypothyroidism 2.
Splenectomy: Associated with increased risk of complications; consider carefully based on individual patient factors 2.Special Populations
Pregnancy: Specific management guidelines not detailed in provided abstracts.
Pediatrics: Management focuses on monitoring and preventing complications like iron overload and organ dysfunction; transfusion therapy may be indicated based on severity 2.
Elderly: Older age independently increases risk of complications; tailored management with emphasis on iron chelation and monitoring for PHT, EMH, and endocrinopathies 2.
Comorbidities: Endocrinopathies are a significant concern, especially with transfusion therapy; iron chelation therapy is recommended to mitigate these risks 2.Key Recommendations
Regular monitoring of liver iron concentration and neurological function using MRI and PET-CT to detect early signs of organ damage and covert infarctions (Evidence: Moderate 1).
Consider transfusion therapy selectively to prevent major complications such as thrombosis, EMH, and heart failure, while closely monitoring for potential endocrinopathies (Evidence: Moderate 2).
Implement iron chelation therapy to mitigate risks of endocrinopathies and PHT, especially in patients with significant iron overload (Evidence: Moderate 2).References
1 Musallam KM, Nasreddine W, Beydoun A, Hourani R, Hankir A, Koussa S et al.. Brain positron emission tomography in splenectomized adults with β-thalassemia intermedia: uncovering yet another covert abnormality. Annals of hematology 2012. link
2 Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S et al.. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010. link